Atricure, Inc. (ATRC) Tops Q2 EPS by 3c, Boosts FY Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
AtriCure Reports Second Quarter 2015 Financial Results and Updates 2015 Outlook
July 28, 2015 4:02 PM EDTRevenue of $32.6 million up 22.9% as reported, 26.5% constant currency U.S. sales of $25.7 million up 29.3% International sales of $6.8 million up 3.5% as reported, 17.9% constant currency
WEST CHESTER, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation and left atrial appendage management, today announced second quarter 2015 financial results.
We are pleased by our results this quarter which reflect continued stability in our business and the solid foundation AtriCure is building for future growth, said... More
